Ace Therapeutics
Ace Therapeutics is a preclinical contract research service provider dedicated to offering comprehensive and tailored preclinical research solutions. They focus on various therapeutic areas including glaucoma, cardiovascular diseases, diabetes, inflammatory bowel disease (IBD), and drug resistance. Their mission is to support the development of innovative therapies through high-quality, reliable, and efficient preclinical services, including efficacy testing, pharmacokinetics, toxicology, and biomarker development. They aim to accelerate drug development processes and provide one-stop solutions for researchers worldwide.
Industries
Nr. of Employees
small (1-50)
Ace Therapeutics
New York, New York, United States, North America
Products
BTN1A1 Polyclonal Antibody
Affinity-purified polyclonal rabbit antibody targeting human BTN1A1; supplied unconjugated for western blot applications; reactive in mouse and rat.
Oxeglitazar (research compound)
Small-molecule research compound (CAS 280585-34-4) described as an orally active agent for type II diabetes research; supplied in multiple sizes.
Rabbit Atg5 (D5F5U) Monoclonal Antibody
Rabbit monoclonal antibody against human ATG5 suitable for western blot and immunoprecipitation; affinity-purified, supplied in liquid format.
Napabucasin (research compound)
Orally available small-molecule inhibitor (CAS 83280-65-3) provided as research-grade material; described as a STAT3 and cancer stemness inhibitor.
AG14361 (PARP inhibitor, research compound)
PARP-1 inhibitor provided as research-grade solid or solution; includes potency data and storage instructions for preclinical use.
Antroquinonol (natural-product derivative)
Ubiquinone derivative provided for research on inflammation and cancer-related endpoints; available in solid form.
BTN1A1 Polyclonal Antibody
Affinity-purified polyclonal rabbit antibody targeting human BTN1A1; supplied unconjugated for western blot applications; reactive in mouse and rat.
Oxeglitazar (research compound)
Small-molecule research compound (CAS 280585-34-4) described as an orally active agent for type II diabetes research; supplied in multiple sizes.
Rabbit Atg5 (D5F5U) Monoclonal Antibody
Rabbit monoclonal antibody against human ATG5 suitable for western blot and immunoprecipitation; affinity-purified, supplied in liquid format.
Napabucasin (research compound)
Orally available small-molecule inhibitor (CAS 83280-65-3) provided as research-grade material; described as a STAT3 and cancer stemness inhibitor.
AG14361 (PARP inhibitor, research compound)
PARP-1 inhibitor provided as research-grade solid or solution; includes potency data and storage instructions for preclinical use.
Antroquinonol (natural-product derivative)
Ubiquinone derivative provided for research on inflammation and cancer-related endpoints; available in solid form.
Services
One-stop preclinical study services covering model development, efficacy, PK/PD, safety and biomarker work for academic and industry clients.
Design and execution of customized in vivo animal models (genetic, chemically induced, diet-induced, surgical, spontaneous) for disease study and drug evaluation.
Provision of cell-line based models, organoid systems, pancreatic islet models and ex vivo tissue assays for mechanism and screening studies.
PK profiling and DMPK studies to characterize absorption, distribution, metabolism and excretion properties of candidate compounds.
Safety evaluation and toxicology testing in laboratory and animal studies to assess candidate risk profiles.
Development of molecular, tissue and functional biomarkers to support PD readouts and translational research (including vascular and glucose-related biomarkers).
One-stop preclinical study services covering model development, efficacy, PK/PD, safety and biomarker work for academic and industry clients.
Design and execution of customized in vivo animal models (genetic, chemically induced, diet-induced, surgical, spontaneous) for disease study and drug evaluation.
Provision of cell-line based models, organoid systems, pancreatic islet models and ex vivo tissue assays for mechanism and screening studies.
PK profiling and DMPK studies to characterize absorption, distribution, metabolism and excretion properties of candidate compounds.
Safety evaluation and toxicology testing in laboratory and animal studies to assess candidate risk profiles.
Development of molecular, tissue and functional biomarkers to support PD readouts and translational research (including vascular and glucose-related biomarkers).
Expertise Areas
- Preclinical contract research
- Disease modeling (in vivo, in vitro, ex vivo)
- Antidiabetic drug discovery and development
- Glaucoma preclinical research
Key Technologies
- In vivo animal models
- In vitro cell models and organoids
- Ex vivo tissue models
- Gene editing and vector construction
News & Updates
Researchers are conducting numerous trials to study glaucoma with the goal of improving diagnosis, management, and treatment. Strategies include laser therapy, surgical options, and drug therapy with various drug classes.
An overview of glaucoma, its development, symptoms, risk factors, and treatment strategies, including laser, surgical, and drug therapies.
Researchers are conducting numerous trials to study glaucoma with the goal of improving diagnosis, management, and treatment. Strategies include laser therapy, surgical options, and drug therapy with various drug classes.
An overview of glaucoma, its development, symptoms, risk factors, and treatment strategies, including laser, surgical, and drug therapies.